What next for newly diagnosed glioblastoma?

Evidio Domingo-Musibay, Evanthia Galanis

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

Glioblastoma is the most common primary brain tumor in adults. Despite current multimodality treatment including surgical resection and temozolomide-based chemoradiotherapy, median survival is only 14-16 months. Characterization of molecular alterations in glioblastoma has identified prognostic subgroups and therapeutic opportunities for clinical trials across glioblastoma subsets. Following a number of negative Phase III trials testing temozolomide dose intensification and angiogenesis inhibition, recent interim analysis data indicate survival prolongation with use of a device (Optune™) delivering alternating electrical field therapy in newly diagnosed glioblastoma patients. In this review, we present an overview of the data supporting the current standard of care and discuss novel experimental therapies in early and late phase clinical testing including devices, small molecule drugs, angiogenesis inhibitors, oncolytic virotherapy and immunotherapy.

Original languageEnglish (US)
Pages (from-to)3273-3283
Number of pages11
JournalFuture Oncology
Volume11
Issue number24
DOIs
StatePublished - Dec 2015

Keywords

  • bevacizumab
  • glioblastoma
  • newly diagnosed
  • novo-TTF
  • radiation therapy
  • temozolomide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'What next for newly diagnosed glioblastoma?'. Together they form a unique fingerprint.

Cite this